Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia

Roche

Status: Completed

Conditions: Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02461316

ML25066

Details and patient eligibility

About

Evaluation of safety profile and tolerability of MabThera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of Chronic Lymphocytic Leukemia (CLL).

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients older than 18 years with diagnosed Chronic Lymphocytic Leukemia (CLL)
• CLL stages: Binet stage C (Rai III or IV), Binet stage B (Rai I and II) requiring treatment

Exclusion criteria

• Patients who are not eligible for rituximab treatment according to Summary of Product Characteristics (SmPC)

Trial design

22 participants in 1 patient group

Combination Treatment in Chronic Lymphocytic Leukemia (CLL)

Description:

All participants receiving combination treatment in Chronic Lymphocytic Leukemia (CLL)

Treatment:

Other: No intervention